Bio-Gene Technology (ASX:BGT) Other Stockholders Equity: A$0.00 Mil (As of Dec. 2025)


What is Bio-Gene Technology Other Stockholders Equity?

Bio-Gene Technology ASX:BGT Other Stockholders Equity is A$0.00 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's Other Stockholders Equity for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Bio-Gene Technology's quarterly Other Stockholders Equity increased from Dec. 2024 (A$-0.00 Mil) to Jun. 2025 (A$0.00 Mil) and increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.00 Mil).

Bio-Gene Technology's annual Other Stockholders Equity increased from Jun. 2023 (A$-0.00 Mil) to Jun. 2024 (A$-0.00 Mil) and increased from Jun. 2024 (A$-0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Bio-Gene Technology Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Other Stockholders Equity Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 -0.00 -0.00 -0.00 0.00

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 0.00 0.00

Bio-Gene Technology Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of A$0.00 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Other Stockholders Equity of A$0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Other Stockholders Equity too high?
Bio-Gene Technology's current Other Stockholders Equity is A$0.00 Mil.
How does Bio-Gene Technology's Other Stockholders Equity compare to VRTX and REGN?
Bio-Gene Technology's Other Stockholders Equity of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Other Stockholders Equity is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Other Stockholders Equity of A$0.00 Mil. The current Other Stockholders Equity is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Other Stockholders Equity is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.